Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2020) 70 AEP1070 | DOI: 10.1530/endoabs.70.AEP1070

ECE2020 Audio ePoster Presentations Hot topics (including COVID-19) (110 abstracts)

Efficacy of lanreotide autogel for chinese patients with active acromegaly with or without prior pituitary surgery: A post hoc analysis of the Lantern study

zhenmei An 1 , Ting Lei 2 , lian Duan 3 , Lihui Zhang 4 , Su Zhou 5 , Xiaofeng Shi 6 & Gu Feng 3

1West China Hospital, Sichuan Universtiy, Endocrinology, Chengdu, China; 2Tongji Hospital, Tongji Medical college of HUST, Neurosurgery, Wuhan, China; 3Peking Union Medical College Hospital, PUMCH, Endocrinology, Beijing, China; 4The second hospital of Hebei Medical Universty, Endocrinology, Shijiazhuang, China; 5Ipsen Pharma, Endocrinology, Beijing, China; 6Ipsen Innovation, Endocrinology, Shanghai, China

Background: Previous studies have yielded conflicting results on biochemical control with medical therapy in patients with or without prior pituitary surgery. The LANTERN study (NCT02493517) demonstrated that lanreotide autogel (LAN ATG) was non-inferior to lanreotide prolonged release (LAN PR) in Chinese patients with active acromegaly. This post hoc analysis of the LANTERN study aimed to explore the efficacy of LAN ATG in patients with or without prior pituitary surgery.

Design: Patients with active acromegaly were randomized to LAN ATG or LAN PR 40 mg for 32 weeks. This post hoc analysis focuses on the efficacy of LAN ATG in patients with (Group I) or without (Group II) prior pituitary surgery.

Results: There were 39 patients in Group I and 18 patients in Group II at Baseline. The median time since acromegaly diagnosis prior to Baseline was longer in Group I [median (Q1,Q3) 3.37 (] than Group II [0.44 ( years; P = 0.001]. Group I had higher age-adjusted mean Baseline IGF-1 standard deviation scores (SDS) than Group II (17.37 ± 5.28 vs 13.65 ± 6.11; P = 0.03). Baseline GH level was comparable between Group I and II [10.37 ( vs 18.84 (; P = 0.226]. Change in IGF-1 SDS from Baseline at Week 32 was –7.16 (95% CI in Group I vs –4.96 (95% CI –7.84, –2.08) in group II (P = 0.218). The proportion of patients achieving IGF-1 normalization at Week 32 in Group I (20.5%, 8/39) was almost twice that in Group II (11.1%, 2/18) (P = 0.622). Change in GH levels from Baseline at Week 32 was comparable between Group I and II [–10.94 (95% CI –16.16, –5.71) vs –11.50 (95% CI –19.21, –3.78); P = 0.905]. 28.2% (11/39) and 27.8% (5/18) patients in Group I and II attained GH levels ≤ 2.5 µg/L, respectively (P = 0.973). Among patients with evaluable MRI both at Baseline and post-treatment, 39.4% (13/33) in Group I and 37.5% (6/16) in Group II achieved ≤ 20% reduction in tumor volume, respectively (P = 0.899). The rate of treatment-emergent adverse events (TEAEs) was 94.9% in Group I and 88. 9% in Group II. The rate of severe and moderate TEAEs was lower in Group I (43.6%) than Group II (83.3%).

Conclusion: In the LANTERN study, patients with prior surgery had longer history of acromegaly and higher Baseline IGF-1 scores than those without. LAN ATG provided comparable biochemical control and tumor volume reduction in patients with or without prior pituitary surgery. The results indicate that prior pituitary surgery does not significantly affect the treatment efficacy and safety of LAN ATG.

Volume 70

22nd European Congress of Endocrinology

05 Sep 2020 - 09 Sep 2020

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.